Needham Reiterates Buy on Harmony Biosciences, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences (NASDAQ:HRMY) and maintains a $67 price target.
May 30, 2023 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia reiterates a Buy rating on Harmony Biosciences and maintains a $67 price target.
The news directly mentions Harmony Biosciences (HRMY) and the analyst's Buy rating and maintained price target of $67. This reaffirmation of a positive rating by a reputable analyst is likely to have a positive short-term impact on the stock price, as it signals confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100